Niacinamide: The Forgotten B Vitamin Beating Glucosamine for Knee Pain

Niacinamide (nicotinamide), the amide form of vitamin B3, has been studied for osteoarthritis since the 1950s, when William Kaufman documented functional joint improvements in hundreds of patients taking 900–4,000 mg/day. Kaufman's observational work was dismissed for decades, but a small controlled trial by Jonas and colleagues (1996, PMID 8841834) randomized 72 patients with osteoarthritis to 3,000 mg/day niacinamide or placebo for 12 weeks. Global arthritis impact improved by 29% (95% CI 6–46; p=0.04) on niacinamide while worsening by about 10% on placebo, anti-inflammatory drug use dropped 13%, and joint mobility improved by 4.5° over controls. The effect size is comparable to or exceeds what glucosamine has shown in head-to-head indirect comparisons, though Jonas was a single small pilot trial and has not been replicated at scale.

A Different Mechanism Entirely

Unlike NSAIDs (COX inhibition) or glucosamine (cartilage substrate provision), niacinamide appears to act as a precursor to NAD+, supporting chondrocyte mitochondrial function and suppressing inflammatory cytokines (IL-1, TNF-α). High-dose niacinamide has also been shown to inhibit osteoarthritis-associated nitric oxide synthase activity in cartilage explants. This places it mechanistically closer to emerging NAD+ boosters (NR, NMN) than to classical joint supplements.

Dosing and Flush Distinction

Critical point: this is niacinamide, not niacin. Niacin (nicotinic acid) causes the flushing reaction and carries liver toxicity at high doses; niacinamide does not flush and has a much better safety profile, though doses above 3,000 mg/day should be monitored for liver enzymes. The Jonas protocol uses 500 mg six times daily — divided dosing matters because plasma half-life is short (about 4 hours).

Where This Sits Clinically

Niacinamide has not become mainstream for osteoarthritis because that single 72-patient RCT has not been replicated at scale — a pattern common to generic, unpatentable molecules. But the mechanistic rationale is strong, the cost is trivial (about $5/month), and the safety margin at 3,000 mg/day is wide as long as liver enzymes are checked periodically. For patients who have failed glucosamine/chondroitin or wish to complement them, niacinamide is a reasonable evidence-informed addition with a distinct mechanism.